KMT2A and acute myeloid leukemia: To further examine the specificity of CAD204520, we performed a comparable treatment with the commonly used AML chemotherapeutic agent cytarabine and CAD204520 to induce dose-dependent apoptosis in our CRISPR/Cas9 MLL-AF4 and MLL-AF9 cells (Figure 3A) and consequently assessed the NOTCH1 receptor and target gene expression using flow cytometry and qPCR, respectively.